DE59712555D1
(de)
*
|
1996-06-05 |
2006-04-06 |
Roche Diagnostics Gmbh |
Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
|
ATE417622T1
(de)
|
1996-08-08 |
2009-01-15 |
Amylin Pharmaceuticals Inc |
Regulation gastrointestinaler beweglichkeit
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
EP1629849B2
(de)
|
1997-01-07 |
2017-10-04 |
Amylin Pharmaceuticals, LLC |
Pharmazeutische Zusammensetzungen enthaltend Exendine und deren Agonisten
|
ES2293688T5
(es)
*
|
1997-08-08 |
2011-05-04 |
Amylin Pharmaceuticals, Inc. |
Nuevos compuestos análogos de la exendina.
|
EP1938831A1
(de)
*
|
1997-08-08 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Neue Exendinagonist-Verbindungen
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
EP1938830A1
(de)
*
|
1997-11-14 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Neue Exendinagonist-Verbindungen
|
AU2003200129B2
(en)
*
|
1997-11-14 |
2006-06-22 |
Amylin Pharmaceuticals, Llc |
Novel Exendin Agonist Compounds
|
WO1999025727A2
(en)
|
1997-11-14 |
1999-05-27 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
EP1941900A1
(de)
*
|
1997-11-14 |
2008-07-09 |
Amylin Pharmaceuticals, Inc. |
Neue Exendinagonist-Verbindungen
|
AU2006225176B2
(en)
*
|
1997-11-14 |
2009-01-08 |
Amylin Pharmaceuticals, Llc |
Novel exendin agonist compounds
|
ATE383867T1
(de)
*
|
1997-11-14 |
2008-02-15 |
Amylin Pharmaceuticals Inc |
Neuartige exendin agonisten
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
WO1999040788A1
(en)
*
|
1998-02-13 |
1999-08-19 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and glp-1
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
KR100637433B1
(ko)
|
2004-05-24 |
2006-10-20 |
삼성에스디아이 주식회사 |
발광 표시 장치
|
EP1056775B1
(de)
*
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
|
ES2335066T3
(es)
*
|
1998-08-10 |
2010-03-18 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Diferenciacion de celulas no productoras de insulina en celulas productoras de insulina glp-1 o exendina-4 y utilizaciones de las mismas.
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
KR100675711B1
(ko)
|
1999-01-14 |
2007-02-01 |
아밀린 파마슈티칼스, 인크. |
신규 엑센딘 아고니스트 제제 및 이의 투여 방법
|
AU770712B2
(en)
|
1999-01-14 |
2004-02-26 |
Amylin Pharmaceuticals, Inc. |
Methods for glucagon suppression
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
AU775063C
(en)
*
|
1999-04-30 |
2005-05-12 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
AU754770B2
(en)
|
1999-05-17 |
2002-11-21 |
Conjuchem Biotechnologies Inc. |
Long lasting insulinotropic peptides
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(de)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptide zur Senkung des Blutglukosespiegels
|
EP1270011A4
(de)
*
|
2000-02-18 |
2003-06-11 |
Sumitomo Pharma |
Wirkstoffe zur verbesserung von gestörter glukosetoleranz
|
WO2001066018A1
(en)
*
|
2000-03-03 |
2001-09-13 |
C. R. Bard, Inc. |
Endoscopic tissue apposition device with multiple suction ports
|
ES2435094T3
(es)
|
2000-05-19 |
2013-12-18 |
C.R. Bard, Inc. |
Dispositivo y método de captura y sutura de tejido
|
EA005584B1
(ru)
|
2000-12-07 |
2005-04-28 |
Эли Лилли Энд Компани |
Слитые белки glp-1
|
WO2002066511A2
(en)
|
2001-02-16 |
2002-08-29 |
Conjuchem Inc. |
Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
|
US20050148497A1
(en)
|
2002-02-20 |
2005-07-07 |
Khan Mohammed A. |
Method for administering glp-1 molecules
|
EP1525219B1
(de)
|
2002-07-04 |
2009-05-27 |
Zealand Pharma A/S |
Glp-1 und behandlungsmethode für diabetes
|
RU2376314C2
(ru)
|
2002-10-02 |
2009-12-20 |
Зилэнд Фарма А/С |
Стабилизированные соединения эксендина-4
|
CA2501677A1
(en)
*
|
2002-10-22 |
2004-05-06 |
Waratah Pharmaceuticals, Inc. |
Treatment of diabetes
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
ES2727854T3
(es)
|
2003-11-20 |
2019-10-21 |
Novo Nordisk As |
Formulaciones de péptidos que contienen propilenglicol que son óptimas para la producción y para su uso en dispositivos de inyección
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
AU2005207870B2
(en)
*
|
2004-01-30 |
2010-08-19 |
Waratah Pharmaceuticals, Inc. |
The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
EP2230257A1
(de)
|
2004-04-23 |
2010-09-22 |
ConjuChem Biotechnologies Inc. |
Verfahren zur Reinigung von Albuminkonjugaten
|
US8172857B2
(en)
*
|
2004-08-27 |
2012-05-08 |
Davol, Inc. |
Endoscopic tissue apposition device and method of use
|
CN101094689B
(zh)
|
2004-11-01 |
2013-06-12 |
安米林药品有限责任公司 |
治疗肥胖以及肥胖相关疾病和病症的方法
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP1841796A2
(de)
|
2004-12-02 |
2007-10-10 |
Domantis Limited |
Bispezifische domänen-antikörper gegen serum albumin und glp-1 oder pyy
|
EP1841448A2
(de)
*
|
2004-12-30 |
2007-10-10 |
Diakine Therapeutics, Inc. |
Pharmazeutische zusammensetzungen und vefahren zur wiederherstellung der betazellmasse und funktion
|
EP1845105A4
(de)
|
2005-01-14 |
2009-02-18 |
Wuxi Grandchamp Pharmaceutical |
Modifizierte exendine und anwendungen davon
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US8404637B2
(en)
|
2005-02-11 |
2013-03-26 |
Amylin Pharmaceuticals, Llc |
GIP analog and hybrid polypeptides with selectable properties
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
CN100429227C
(zh)
*
|
2005-06-29 |
2008-10-29 |
常州制药厂有限公司 |
Exendin4多肽片段
|
EP1922336B1
(de)
*
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybridpolypeptide mit auswählbaren eigenschaften
|
SI1971362T1
(sl)
|
2005-08-19 |
2015-03-31 |
Amylin Pharmaceuticals, Llc |
Eksendin za zdravljenje diabetesa in zmanjšanje telesne mase
|
AU2006288703B2
(en)
*
|
2005-09-06 |
2011-09-22 |
Oramed Pharmaceuticals, Inc. |
Methods and compositions for oral administration of proteins
|
EP1937297A2
(de)
*
|
2005-09-08 |
2008-07-02 |
Gastrotech Pharma A/S |
Verwendung eines glp-1-moleküls zur behandlung von biliärer dyskinesie und/oder biliären schmerzen/beschwerden
|
ES2397289T3
(es)
*
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
AU2006329215A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Conjuchem Biotechnologies Inc. |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
DE602006009631D1
(de)
*
|
2006-05-10 |
2009-11-19 |
Biocompatibles Uk Ltd |
GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
|
CA2651855C
(en)
|
2006-05-30 |
2011-08-02 |
Intarcia Therapeutics, Inc. |
Two-piece, internal-channel osmotic delivery system flow modulator
|
EP2046826B1
(de)
|
2006-07-24 |
2011-09-14 |
Biorexis Pharmaceutical Corporation |
Exendin-fusionsproteine
|
EP2359808B1
(de)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Osmotisches Verabreichungssystem mit Kolbenanordnung
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
CL2007002634A1
(es)
*
|
2006-09-13 |
2008-05-16 |
Smithkline Beecham Corp |
Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
EP1972349A1
(de)
*
|
2007-03-21 |
2008-09-24 |
Biocompatibles UK Limited |
Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
|
WO2008116294A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Matregen Corp. |
Exendin analogs
|
EP1975176A1
(de)
*
|
2007-03-27 |
2008-10-01 |
Biocompatibles UK Limited |
Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
|
ES2402172T3
(es)
|
2007-04-23 |
2013-04-29 |
Intarcia Therapeutics, Inc |
Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
|
US8236760B2
(en)
*
|
2007-04-27 |
2012-08-07 |
Cedars-Sinsai Medical Center |
Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
|
WO2009033740A2
(en)
*
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
US20090186819A1
(en)
*
|
2007-12-11 |
2009-07-23 |
Marieve Carrier |
Formulation of insulinotropic peptide conjugates
|
EP2240155B1
(de)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
|
BRPI0907077A2
(pt)
|
2008-03-26 |
2016-07-26 |
Oramed Ltd |
métodos e composições para administração oral de proteínas
|
CA2718480A1
(en)
|
2008-03-31 |
2009-10-08 |
Glaxo Group Limited |
Drug fusions and conjugates
|
AU2009245294B2
(en)
*
|
2008-05-05 |
2014-02-20 |
Oramed Ltd. |
Methods and compositions for oral administration of exenatide
|
ES2552646T3
(es)
|
2008-05-21 |
2015-12-01 |
Amylin Pharmaceuticals, Inc. |
Exendinas para disminuir el colesterol y los triglicéridos
|
CA2731236A1
(en)
*
|
2008-07-21 |
2010-01-28 |
Transpharma Medical Ltd. |
Transdermal system for extended delivery of incretins and incretin mimetic peptides
|
US9186412B2
(en)
|
2008-08-18 |
2015-11-17 |
Entera Bio Ltd. |
Methods and compositions for oral administration of insulin
|
KR101760953B1
(ko)
|
2008-09-04 |
2017-07-24 |
아밀린 파마슈티칼스, 엘엘씨. |
비-수성 담체를 이용한 서방성 제형물
|
EP2163243A1
(de)
*
|
2008-09-12 |
2010-03-17 |
Biocompatibles UK Limited |
Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
PT3228320T
(pt)
|
2008-10-17 |
2020-03-26 |
Sanofi Aventis Deutschland |
Combinação de uma insulina e de um agonista do glp-1
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
JP2012511586A
(ja)
|
2008-12-10 |
2012-05-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
医薬組成物
|
JP2012521971A
(ja)
|
2009-03-27 |
2012-09-20 |
グラクソ グループ リミテッド |
薬物融合体および複合体
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
WO2010138671A1
(en)
|
2009-05-28 |
2010-12-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
JP5685401B2
(ja)
*
|
2009-08-10 |
2015-03-18 |
国立大学法人京都大学 |
膵島イメージング用分子プローブ及びその前駆体、並びに、それらの使用
|
EP3323423B1
(de)
|
2009-09-28 |
2020-06-17 |
Intarcia Therapeutics, Inc |
Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
|
SG10201406063XA
(en)
|
2009-09-30 |
2014-11-27 |
Glaxo Group Ltd |
Drug fusions and conjugates with extended half life
|
US20120294855A1
(en)
|
2009-11-03 |
2012-11-22 |
Eli Lilly & Company |
Glp-1 receptor agonist compounds for obstructive sleep apnea
|
DE102010011919A1
(de)
|
2010-03-18 |
2011-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
|
US10029011B2
(en)
|
2009-11-13 |
2018-07-24 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
|
PT2498801T
(pt)
|
2009-11-13 |
2018-05-02 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina
|
JP5892940B2
(ja)
|
2009-11-25 |
2016-03-23 |
アリスジェン ソシエテ アノニム |
クラウン化合物及び/又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
|
EP2555791B1
(de)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
|
AU2011247452B2
(en)
|
2010-04-27 |
2016-03-17 |
Zealand Pharma A/S |
Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
|
JP2013525491A
(ja)
|
2010-05-04 |
2013-06-20 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
心血管障害を治療または予防し心血管保護を提供する方法
|
SG187904A1
(en)
|
2010-08-30 |
2013-04-30 |
Sanofi Aventis Deutschland |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
JP6121330B2
(ja)
|
2010-09-28 |
2017-04-26 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続時間が増した改変ポリペプチド
|
US9161953B2
(en)
|
2010-12-22 |
2015-10-20 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonists for islet cell transplantation
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
US20140221282A1
(en)
|
2011-05-25 |
2014-08-07 |
Astrazeneca Pharmaceuticals Lp |
Long duration dual hormone conjugates
|
JP6396211B2
(ja)
|
2011-07-04 |
2018-09-26 |
インペリアル・イノベイションズ・リミテッド |
新規化合物及び摂食行動に対するそれらの効果
|
EP2729481B1
(de)
|
2011-07-08 |
2018-10-17 |
Amylin Pharmaceuticals, LLC |
Manipulierte polypeptide mit verbesserter wirkungsdauer und reduzierter immunogenität
|
KR101983982B1
(ko)
|
2011-08-29 |
2019-05-30 |
사노피-아벤티스 도이칠란트 게엠베하 |
2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
EP2763690B1
(de)
|
2011-10-04 |
2015-11-25 |
Sanofi-Aventis Deutschland GmbH |
Lixisenatide zur behandlung von stenosen oder/und obstruktionen im pankreasgangsystem
|
US20130096059A1
(en)
|
2011-10-04 |
2013-04-18 |
Jens Stechl |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
AU2012331053A1
(en)
|
2011-11-03 |
2014-05-29 |
Zealand Pharma A/S |
GLP-1 receptor agonist peptide gastrin conjugates
|
ES2644962T3
(es)
|
2012-01-03 |
2017-12-01 |
Oramed Ltd. |
Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
|
CN104244969A
(zh)
|
2012-02-01 |
2014-12-24 |
奥拉姆德有限公司 |
含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法
|
IN2014DN09297A
(de)
|
2012-05-16 |
2015-07-10 |
Glaxo Group Ltd |
|
US9745359B2
(en)
|
2012-05-18 |
2017-08-29 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
SG11201407860PA
(en)
|
2012-06-14 |
2014-12-30 |
Sanofi Sa |
Exendin-4 peptide analogues
|
DK2875043T3
(en)
|
2012-07-23 |
2017-03-27 |
Zealand Pharma As |
glucagon
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
UA116553C2
(uk)
|
2012-12-21 |
2018-04-10 |
Санофі |
Пептидна сполука - агоніст рецептора glp-1 i glp
|
CN104902921A
(zh)
|
2013-01-03 |
2015-09-09 |
奥拉姆德有限公司 |
用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
AU2014261111B2
(en)
|
2013-05-02 |
2017-03-16 |
Glaxosmithkline Intellectual Property Development Limited |
Therapeutic peptides
|
EA034322B1
(ru)
|
2013-10-17 |
2020-01-28 |
Зилэнд Фарма А/С |
Ацилированные аналоги глюкагона
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
WO2015067716A1
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
TWI670281B
(zh)
|
2013-11-06 |
2019-09-01 |
西蘭製藥公司 |
Gip-glp-1雙重促效劑化合物及方法
|
EP3077008B1
(de)
|
2013-12-06 |
2023-10-04 |
Jie Han |
Bioreversible pro-elemente für stickstoffhaltige und hydroxylhaltige arzneimittel
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/gip受體促效劑
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/升糖素受體促效劑
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽-4(exendin-4)胜肽類似物
|
EP3080150B1
(de)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
|
MX2016008979A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
|
US9895423B2
(en)
|
2014-01-09 |
2018-02-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
EP3091965A1
(de)
|
2014-01-09 |
2016-11-16 |
Sanofi |
Stabilisierte glycerinfreie pharmazeutische formulierungen von insulinanaloga und/oder insulinderivaten
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
RU2573933C1
(ru)
|
2014-08-21 |
2016-01-27 |
Дафот Энтерпрайсис Лимитед |
Пептид для лечения сахарного диабета 2-го типа и его осложнений
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
MX2017005457A
(es)
|
2014-10-29 |
2017-07-04 |
Zealand Pharma As |
Metodos y compuestos agonistas de gip.
|
NZ733670A
(en)
|
2014-12-12 |
2021-12-24 |
Sanofi Aventis Deutschland |
Insulin glargine/lixisenatide fixed ratio formulation
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
KR20170137198A
(ko)
|
2015-04-16 |
2017-12-12 |
질랜드 파마 에이/에스 |
아실화된 글루카곤 유사체
|
US10660937B2
(en)
|
2015-05-22 |
2020-05-26 |
The Board Of Trustees Of The Leland Stanford Junio |
Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
|
AU2016270984B2
(en)
|
2015-06-03 |
2021-02-25 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
AU2016338410B2
(en)
|
2015-10-14 |
2021-07-15 |
X-Therma, Inc. |
Compositions and methods for reducing ice crystal formation
|
US10294303B2
(en)
|
2015-12-23 |
2019-05-21 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
US10653753B2
(en)
|
2016-03-04 |
2020-05-19 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
|
WO2017178829A1
(en)
*
|
2016-04-15 |
2017-10-19 |
Imperial Innovations Limited |
Peptide analogues
|
KR20240037175A
(ko)
|
2016-05-16 |
2024-03-21 |
인타르시아 세라퓨틱스 인코포레이티드 |
글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
US20190224122A1
(en)
|
2016-09-23 |
2019-07-25 |
Delpor, Inc. |
Stable compositions for incretin mimetic compounds
|
WO2018094404A1
(en)
|
2016-11-21 |
2018-05-24 |
Eiger Biopharmaceuticals, Inc. |
Buffered formulations of exendin (9-39)
|
EP3551202B1
(de)
|
2016-12-06 |
2024-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur erhöhung der wirksamkeit von incretinbasierten arzneimitteln bei darauf angewiesenen personen
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
IL307966A
(en)
|
2017-01-03 |
2023-12-01 |
Intarcia Therapeutics Inc |
Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
MX2019013919A
(es)
|
2017-06-20 |
2020-01-21 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
|
AU2018321157B2
(en)
|
2017-08-24 |
2024-03-28 |
Novo Nordisk A/S |
GLP-1 compositions and uses thereof
|
DK3774838T3
(da)
|
2018-04-10 |
2022-10-31 |
Sanofi Aventis Deutschland |
Lixisenatidsyntese med capping
|
JP7434169B2
(ja)
|
2018-04-10 |
2024-02-20 |
サノフィ-アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
固相からの固相結合ペプチドの切断方法
|
USD933219S1
(en)
|
2018-07-13 |
2021-10-12 |
Intarcia Therapeutics, Inc. |
Implant removal tool and assembly
|
US20220152154A1
(en)
|
2019-03-08 |
2022-05-19 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
IL294520A
(en)
|
2020-02-18 |
2022-09-01 |
Novo Nordisk As |
Pharmaceutical formulations
|